Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that alopecia is a rare side effect of SSRIs, with sertraline showing a higher association compared to citalopram, particularly among women.

This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.

In this study, mild improvements in erectile function, penile sensitivity, and nocturnal erections were observed in male patients with post-drug syndrome following a 16-week treatment targeting the peripheral nerves of the genitalia, but significant symptoms persisted, indicating further research is essential.

The antidepressant escitalopram likely caused hair loss in a patient.

This study suggests that post-finasteride syndrome and post-SSRI sexual dysfunction share potential etiopathogenetic mechanisms involving brain modulators, neurotransmitters, and gut microbiota, although more research is needed to understand these conditions fully.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This research suggests that the drugs trazodone and chlorpromazine, which have effects on specific receptors, may help restore libido synaptic circuits and potentially treat sexual dysfunction associated with post-SSRI and post-finasteride syndromes.

The researchers reported an increased risk of malignant melanoma and nonmelanoma skin cancers with the use of angiotensin-receptor blockers, angiotensin-converting enzyme inhibitors, and thiazides in a large patient study.

This review discusses post-SSRI sexual dysfunction and post-finasteride syndrome, highlighting unknowns about their true incidence and underlying causes, and reports no new clinical results.

This study found that males treated with serotonergic antidepressants had an increased risk of erectile dysfunction, with an adjusted odds ratio of 3.2, and the risk for post-SSRI sexual dysfunction was 0.46%, emphasizing the importance of informed consent due to these potential irreversible side effects.

This review discusses the clinical features of trichotillomania and the challenges in its diagnosis and treatment, reporting no new clinical findings while highlighting the need for specialized therapy and better therapeutic options.

This review discusses the potential for SSRIs to cause serious skin reactions and suggests considering alternative antidepressants if such reactions occur.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

This review discusses adverse cutaneous drug reactions associated with antidepressants and provides guidance on managing these reactions, but it reports no new clinical findings; the authors recommend cautious use and alternative treatment if reactions occur.

This review discusses the complex interplay between the nervous system and skin conditions, highlighting various treatment strategies, but reports no new research findings.

This review discusses psychocutaneous syndromes, detailing their classifications and management strategies, but reports no new clinical findings; it underscores dermatologists' role in these cases.

This study found that transdermal testosterone significantly increased the frequency of satisfactory sexual events in women experiencing SSRI/SNRI-related loss of libido, but did not improve overall sexual self-rating scores.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This review discusses the diagnostic and treatment challenges of trichotillomania and emphasizes the need for better-designed studies to optimize treatment approaches.

This review examines the use of monoaminergic antidepressants for inflammatory skin disorders and reports they may reduce dermatological symptoms, suggesting a potential role beyond treating psychiatric conditions.

This review discusses common psychodermatologic conditions and provides practical diagnostic and therapeutic recommendations but reports no new results; the authors emphasize the challenge of treating patients who lack insight into their psychiatric symptoms.

This review discusses the importance of recognizing and treating psychiatric conditions in dermatology patients, offering practical recommendations for dermatologists to manage psychocutaneous diseases effectively, but reports no new clinical results.

This preliminary study suggests that baseline central serotonin turnover, indicated by CSF 5-HIAA levels, may influence treatment response to serotonin re-uptake inhibitors in women with trichotillomania.

This review discusses trichotillomania, its prevalence, and treatment options, emphasizing that many sufferers experience delays in treatment due to secrecy and shame, but reports no new research findings.

This review discusses adverse effects associated with pegylated IFN therapy for chronic hepatitis C and highlights the potential of new antiviral drugs to reduce side effects and improve treatment adherence, but reports no new clinical results.

This review discusses OCD spectrum disorders with dermatological symptoms, emphasizing their clinical features, neurobiology, and treatment options, while noting the need for more controlled studies.

This review discusses the role of gut steroids in communicating with the gut microbiota and their potential implications in treating gastrointestinal disorders and related brain conditions, suggesting new perspectives on steroid molecules as therapeutic agents.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This review discusses trichotillomania, including its diagnosis and management, and emphasizes the importance of a psychiatry-dermatology liaison alongside behavioral therapy and pharmacological options.